- Home
- Companies
- north america
- cancer patients
Show results for
Refine by
Cancer Patients Suppliers In North America
112 companies found
based inMelville, NEW YORK (USA)
FONAR was incorporated in 1978, making it the first, oldest and most experienced MR manufacturer in the industry. FONAR introduced the world's first commercial MRI (a whole-body MRI scanner) in 1980, and went public in 1981. In 1982, FONAR ...
based inOrlando, FLORIDA (USA)
Asbestos.com is a website and advocacy group that helps the victims of asbestos exposure and their loved ones. We connect our visitors with the resources they need to understand and fight asbestos-related disease, all at no cost. We research the ...
Cryotherapy is a cancer treatment that kills cells by exposing them to extreme cold. Because living tissues cannot survive in drastically cold conditions, radiologists can use this therapy to induce hypothermia and kill solid tumors ...
based inSouth San Francisco, CALIFORNIA (USA)
Veracyte is a pioneering genomic diagnostics company. Our tests provide trustworthy and actionable ANSWERS that improve care throughout the patient journey. We ask the right questions and provide answers that give physicians and patients a clearer ...
Avoiding unnecessary procedures, speeding time to diagnosis and appropriate treatment. Lung cancer is the leading cancer killer worldwide, causing approximately 1.8 million deaths each year. Veracyte’s ...
based inTucson, ARIZONA (USA)
D3Sciences is dedicated to the development of tools for improved tissue sampling to expand cancer diagnosis, therapy specificity, and research. Creating tools to improve tissue sampling for rapid, precise, and cost effective delivery of care to ...
Detecting, Diagnosing and Treating Cancer: To detect, diagnose, and treat internal cancer requires a team of healthcare providers led generally by three specialist physicians: oncologists, radiologists, and ...
based inIrvine, CALIFORNIA (USA)
MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The Company’s tests are based on ...
based inRedwood City, CALIFORNIA (USA)
Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. We’re developing blood tests for early detection in high-risk populations and ...
based inParis Cedex 06, FRANCE
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...
based inNew York, NEW YORK (USA)
Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build ...
based inSouth San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
based inHouston, TEXAS (USA)
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide immunotherapy, and has commenced a Phase III clinical trial, called Flamingo-01. GP2 is derived ...
Cancer Immunotherapies are a New Method of Cancer Treatment. Among the more established treatment options, such as surgery, chemotherapy, targeted therapy, and radiation therapy, cancer ...
based inAlbuquerque, NEW MEXICO (USA)
Indica Labs is the world’s leading provider of computational pathology software and services. Our flagship HALO image analysis platform enables fast, quantitative evaluation of tissues using a broad range of artificial intelligence (AI) and computer ...
HALO AI is a collection of train-by-example classification and segmentation tools underpinned by advanced deep learning neural network algorithms. HALO AI classifiers can be trained to quantify tissue classes, to segment tissue classes for analysis ...
based inFriendswood, TEXAS (USA)
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and ...
A Focus on Transforming Disease Management. Our approach to product development starts by identifying areas of unmet medical need where precision medicine could significantly improve disease staging and/or patient care decisions. We focus first on ...
based inSan Diego, CALIFORNIA (USA)
We are dedicated to one thing: improving outcomes for cancer patients. That’s why we focus on developing innovative diagnostic solutions that give patients and doctors the information they need—all from a simple blood test, known as a liquid biopsy. ...
based inCleveland, OHIO (USA)
Cleveland Diagnostics, Inc. is a commercial-stage diagnostics company developing highly efficacious, lab-friendly, affordable diagnostics tests using proprietary technology to improve cancer diagnostics. The Company’s Solvent Interaction Analysis ...
IsoPSA Proceed to biopsy only when needed. IsoPSA is now included in NCCN® Prostate Cancer Early Detection Guidelines. IsoPSA can help reduce unnecessary prostate biopsies by up to 55%. Up to 75% of results from prostate biopsies performed in ...
based inMarseille Cedex 9, FRANCE
Veracyte, formerly HalioDx, is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. Our ...
Designed to deliver critical information to guide chemotherapy decision-making, Immunoscore® can be used in Stage II localized colon cancer to help physicians identify patients who may be spared ...
based inSeattle, WASHINGTON (USA)
Navigating Cancer develops innovative technology solutions to improve oncology care. Navigating Cancer was founded in 2008 with the goal of filling a critical gap in oncology care: a better patient experience. That’s why we created the first ...
Provide streamlined care coordination through standardized orders and care pathways. Stratify patients into care populations and prioritize management of high-risk patients. Automatically assign tasks to the appropriate staff member (so patients ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in ovarian ...
based inFremont, CALIFORNIA (USA)
BioGenex designs, develops and commercializes molecular pathology systems for Tumor diagnosis, prognosis, precision medicine and life science research. BioGenex’s industry-leading next-generation cytogenetic FISH workflow solution and miRNA system ...
based inPrinceton, NEW JERSEY (USA)
Taiho Oncology, Inc. specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a ...
based inPrinceton, NEW YORK (USA)
We are a biopharmaceutical company dedicated to building novel solutions that treat urothelial and specialty cancers. Our breakthrough therapy and innovative clinical pipeline aim to maximize the potential benefit of local delivery with our novel ...
UGN-301 is UroGen’s in-licensed anti-CTLA-4 antibody (zalifrelimab). UGN-201 is our proprietary formulation of imiquimod, a toll-like receptor 7 (TLR 7) agonist. When combined, these medicines stimulate both the innate (UGN-201) and adaptive ...